Share price weakness of late, should be capitalised on
04/09/26 -"We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) candidates, we have reduced the premium on ..."
Pages
72
Language
English
Published on
04/09/26
You may also be interested by these reports :
04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...
04/09/26
We have tweaked our earnings estimates lower and considering the recent late-stage setbacks for cardiovascular (Wainua) and oncology (Volrustomig) ...
27/08/26
While immense pricing and competitive pressures from Eli Lilly and compounding pharmacies have proven to be a nightmare for Novo Nordisk in the last ...
26/08/26
We upgrade Novonesis to ADD from Reduce. The Q2 26 results marked a clear inflection point: broad-based organic growth (+9%, well ahead of consensus) ...